{"id":68024,"date":"2026-06-11T21:15:16","date_gmt":"2026-06-11T13:15:16","guid":{"rendered":"https:\/\/flcube.com\/?p=68024"},"modified":"2026-06-11T21:15:17","modified_gmt":"2026-06-11T13:15:17","slug":"quantumpharm-xtalpi-secures-400-million-ai-driven-partnership-for-best-in-class-gpcr-targeting-oral-small-molecule-drug","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68024","title":{"rendered":"QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>QuantumPharm Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2228:HKG\">HKG: 2228<\/a>), operating as <strong>XtalPi Inc.<\/strong>, announced a <strong>strategic AI-powered collaboration<\/strong> with an <strong>internationally renowned biopharmaceutical company<\/strong> featuring a <strong>robust pipeline and multiple commercialized products<\/strong>, in a deal valued at <strong>over USD 400 million<\/strong> to jointly develop an <strong>innovative oral small-molecule drug<\/strong> with <strong>&#8220;Best-in-Class&#8221; potential<\/strong> targeting a <strong>G protein-coupled receptor (GPCR)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-financial-terms\" class=\"wp-block-heading\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>QuantumPharm\/XtalPi (HKG: 2228) + International biopharma (undisclosed)<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>AI-powered drug discovery and development<\/td><\/tr><tr><td><strong>Therapeutic Target<\/strong><\/td><td>G protein-coupled receptor (GPCR)<\/td><\/tr><tr><td><strong>Drug Modality<\/strong><\/td><td>Oral small-molecule with Best-in-Class potential<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>Undisclosed amount to XtalPi<\/td><\/tr><tr><td><strong>R&amp;D Funding<\/strong><\/td><td>Full early-stage R&amp;D costs covered by collaborator<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Preclinical, clinical, and commercial milestones<\/td><\/tr><tr><td><strong>Additional Compensation<\/strong><\/td><td>Future royalties on net sales<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td>Over USD 400 million<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>11 Jun 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-technology-platform-amp-innovation\" class=\"wp-block-heading\">Technology Platform &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Capability:<\/strong> XtalPi&#8217;s proprietary AI-driven drug discovery platform combining quantum physics, machine learning, and computational chemistry<\/li>\n\n\n\n<li><strong>Target Class:<\/strong> G protein-coupled receptors (GPCRs) &#8211; representing approximately 34% of all FDA-approved drugs but remaining challenging for novel drug discovery<\/li>\n\n\n\n<li><strong>Development Approach:<\/strong> AI-accelerated hit identification, lead optimization, and preclinical candidate selection<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Collaborator bears all early-stage R&amp;D costs, significantly de-risking XtalPi&#8217;s investment in a challenging target space<\/li>\n\n\n\n<li><strong>Revenue Model:<\/strong> Hybrid structure combining near-term R&amp;D revenue with long-term asset value participation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">GPCRs represent one of the most validated yet challenging target classes in pharmaceutical development, with significant opportunities for Best-in-Class therapies offering improved efficacy, safety, or dosing convenience over existing treatments. XtalPi&#8217;s AI platform enables rapid exploration of chemical space and prediction of compound properties that would be prohibitively expensive or time-consuming using traditional approaches.<\/p>\n\n\n\n<h2 id=\"h-strategic-impact-amp-market-implications\" class=\"wp-block-heading\">Strategic Impact &amp; Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Financial De-risking:<\/strong> Partnership structure eliminates XtalPi&#8217;s upfront R&amp;D investment while preserving substantial upside participation<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Major biopharma partner&#8217;s commitment validates XtalPi&#8217;s AI platform capabilities and target selection strategy<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Positions XtalPi among elite AI-driven drug discovery companies securing nine-figure partnerships<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Reduces reliance on service-based revenue model toward asset-centric value creation<\/li>\n\n\n\n<li><strong>Industry Trend:<\/strong> Reflects growing confidence in AI-native drug discovery companies to deliver clinically viable candidates for high-value targets<\/li>\n\n\n\n<li><strong>Blockbuster Potential:<\/strong> GPCR-targeting oral small molecules historically represent some of pharma&#8217;s most successful drugs, with multiple billion-dollar annual sellers<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The collaboration exemplifies the evolving business model for AI-driven biotech companies, moving beyond pure service agreements toward risk-sharing partnerships that align incentives and maximize value creation from innovative therapeutic assets.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership terms, technological capabilities, and market opportunities. Actual outcomes may differ due to scientific, regulatory, and commercial uncertainties inherent in drug discovery and development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., announced a strategic AI-powered collaboration with an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[99,1112,695,696],"class_list":["post-68024","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ai","tag-hkg-2228","tag-quantumpharm","tag-xtalpi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., announced a strategic AI-powered collaboration with an internationally renowned biopharmaceutical company featuring a robust pipeline and multiple commercialized products, in a deal valued at over USD 400 million to jointly develop an innovative oral small-molecule drug with &quot;Best-in-Class&quot; potential targeting a G protein-coupled receptor (GPCR).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68024\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug\" \/>\n<meta property=\"og:description\" content=\"QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., announced a strategic AI-powered collaboration with an internationally renowned biopharmaceutical company featuring a robust pipeline and multiple commercialized products, in a deal valued at over USD 400 million to jointly develop an innovative oral small-molecule drug with &quot;Best-in-Class&quot; potential targeting a G protein-coupled receptor (GPCR).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68024\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-11T13:15:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-11T13:15:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68024#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68024\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug\",\"datePublished\":\"2026-06-11T13:15:16+00:00\",\"dateModified\":\"2026-06-11T13:15:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68024\"},\"wordCount\":450,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"HKG: 2228\",\"QuantumPharm\",\"Xtalpi\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68024#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68024\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68024\",\"name\":\"QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-11T13:15:16+00:00\",\"dateModified\":\"2026-06-11T13:15:17+00:00\",\"description\":\"QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., announced a strategic AI-powered collaboration with an internationally renowned biopharmaceutical company featuring a robust pipeline and multiple commercialized products, in a deal valued at over USD 400 million to jointly develop an innovative oral small-molecule drug with \\\"Best-in-Class\\\" potential targeting a G protein-coupled receptor (GPCR).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68024#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68024\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68024#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug - Insight, China&#039;s Pharmaceutical Industry","description":"QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., announced a strategic AI-powered collaboration with an internationally renowned biopharmaceutical company featuring a robust pipeline and multiple commercialized products, in a deal valued at over USD 400 million to jointly develop an innovative oral small-molecule drug with \"Best-in-Class\" potential targeting a G protein-coupled receptor (GPCR).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68024","og_locale":"en_US","og_type":"article","og_title":"QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug","og_description":"QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., announced a strategic AI-powered collaboration with an internationally renowned biopharmaceutical company featuring a robust pipeline and multiple commercialized products, in a deal valued at over USD 400 million to jointly develop an innovative oral small-molecule drug with \"Best-in-Class\" potential targeting a G protein-coupled receptor (GPCR).","og_url":"https:\/\/flcube.com\/?p=68024","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-11T13:15:16+00:00","article_modified_time":"2026-06-11T13:15:17+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68024#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68024"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug","datePublished":"2026-06-11T13:15:16+00:00","dateModified":"2026-06-11T13:15:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68024"},"wordCount":450,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","HKG: 2228","QuantumPharm","Xtalpi"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68024#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68024","url":"https:\/\/flcube.com\/?p=68024","name":"QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-11T13:15:16+00:00","dateModified":"2026-06-11T13:15:17+00:00","description":"QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., announced a strategic AI-powered collaboration with an internationally renowned biopharmaceutical company featuring a robust pipeline and multiple commercialized products, in a deal valued at over USD 400 million to jointly develop an innovative oral small-molecule drug with \"Best-in-Class\" potential targeting a G protein-coupled receptor (GPCR).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68024#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68024"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68024#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68024"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68024\/revisions"}],"predecessor-version":[{"id":68026,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68024\/revisions\/68026"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}